Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2023 | Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study | LANCET ONCOLOGY |